{"id":262,"date":"2020-12-23T15:07:50","date_gmt":"2020-12-23T22:07:50","guid":{"rendered":"https:\/\/neurotucson.fm1.dev\/oncology\/recurrent-and-newly-diagnosed-glioblastoma-study\/"},"modified":"2021-03-31T17:56:55","modified_gmt":"2021-03-31T23:56:55","slug":"recurrent-and-newly-diagnosed-glioblastoma-study","status":"publish","type":"page","link":"https:\/\/neurotucson.com\/oncology\/recurrent-and-newly-diagnosed-glioblastoma-study\/","title":{"rendered":"Recurrent and Newly Diagnosed Glioblastoma Study"},"content":{"rendered":"\n
Recurrent and Newly Diagnosed Glioblastoma: BeiGene BGB-290 Study<\/h2>\n\n\n\n
This study is to evaluate the safety, efficacy and clinical activity of BGB-290 in combination with radiation therapy (RT) and\/or temozolomide (TMZ) in subjects with newly diagnosed or recurrent\/refractory glioblastoma.<\/p>\n\n\n\n
Study Enrollment<\/h2>\n\n\n\n
If you, your family member or loved one is interested in learning more about participating in this study, please contact the BeiGene Study Coordinator at 520-320-2157<\/a>.<\/p>\n\n\n\n